BA
HQL

Bard Associates’s abrdn Life Sciences Investors HQL Stock Holding History

Bard Associates’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-13,933
Closed -$303K – 189
2014
Q1 		$303K Sell
13,933
-28,755
-67% -$640K 0.13% 157
2013
Q4 		$873K Sell
42,688
-3,410
-7% -$66.1K 0.36% 97
2013
Q3 		$887K Sell
46,098
-2,070
-4% -$39.6K 0.39% 93
2013
Q2 		$861K Buy
+48,168
New +$870K 0.4% 88

Other funds holding HQL

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BI
Bulldog Investors Saddle Brook, New Jersey $445M AUM 2.55% 1-Year Est. Return

Bard Associates's HQL Position: Q2 2014 in Review

Bard Associates sold out of abrdn Life Sciences Investors (HQL) in Q2 2014, closing a stake of 13,933 shares — an estimated $303K sold.

Bard Associates first reported a position in HQL in Q2 2013 and held it in 4 quarters. The position peaked at $887K in Q3 2013. 54 funds tracked by Wall St. Rank hold HQL as of Q2 2014.

  • Bard Associates reported no remaining abrdn Life Sciences Investors position as of Q2 2014 after selling out during the quarter.
  • Bard Associates sold 13,933 abrdn Life Sciences Investors shares in Q2 2014, an estimated $303K.
  • Bard Associates first reported a position in abrdn Life Sciences Investors in Q2 2013 and held it in 4 quarters.
  • Bard Associates's abrdn Life Sciences Investors position peaked at $887K in Q3 2013.
  • 54 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2014.

Based on Bard Associates's 13F filing for Q2 2014, filed 12 Aug 2014.